Investor Presentaiton

Appendix (Research and Development) Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (as of May 15, 2023) Proposed indication, etc. Partnering Pediatric congenital Region (planned) Revisions since the announcement of January 2023 are shown in red status Cell type Duke University Global Cultured thymus tissue Launched in March 2022 (U.S.) athymia (RETHYMIC®) RPE tear AMD (age-related macular degeneration) Healios Global Allo iPS cell-derived retinal pigment RIKEN Parkinson's disease Kyoto (Designated as a University Global "SAKIGAKE") CIRA Allo iPS cell-derived Retinitis pigmentosa RIKEN Global photoreceptor (3D) Spinal cord injury Keio University Osaka National Hospital Global Allo iPS cell-derived neural progenitor cells Kidney failure Jikei University Bios Japan, North America epithelium cells Allo iPS cell-derived dopamine neural progenitor cells Preparing to start clinical study (Japan) In progress: investigator-initiated study (Phase 1/2 study) (Japan) Preparing to start clinical study (U.S.) In progress: clinical research In progress: clinical research (Sub-Acute Phase) In progress: pre-clinical study (Chronic Phase) Aim to start clinical study in FY2023 Aim to launch in FY2024 (Japan)* Auto/ Allo iPS cell- based induced nephron progenitor cells (organ) * Launch schedule is based on our goal pending agreement with partners In progress: pre-clinical study © Sumitomo Pharma Co., Ltd. All Rights Reserved. 25

View entire presentation